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Conclusion: Culprit lesion calcification on angiography is independently associated with
adverse clinical outcomes in STEMI patients, irrespective of culprit artery patency, pres-
ence of thrombus, age, history of prior MI and disease extent.
1060-84 The Impact of Contemporary Guideline Compliance on 
Risk Stratification Models for Acute Coronary 
Syndromes in The Registry of Acute Coronary 
Syndrome (TRACS)
Martha Gulati, Samir Patel, Allan S. Jaffe, Anthony Joseph, James E. Calvin, Jr., Rush-
Presbyterian-St. Luke’s Medical Center, Chicago, IL, The Mayo Clinic, Rochester, MN
Background: Because acute coronary syndromes (ACS) represent a major public health
issue, risk stratification models for ACS have been developed to aid physicians in deci-
sion-making, directing management and predicting prognosis. This study compares the
predictive value of the RUSH Score and the Thrombolysis in Myocardial Infarction (TIMI)
Risk Score in an unselected patient population with ACS, and evaluates the impact of
compliance with established guidelines on the accuracy of these models. Methods: The
Registry of Acute Coronary Syndromes (TRACS) is a retrospective registry of 3754 con-
secutive patients presenting with ACS to the emergency department between April1,
1999 to December 31, 2000 at 9 participating hospital centers (tertiary and community).
Patients less than 25 years old (N=8) and with incomplete data (N=1) were excluded. The
primary endpoint was all-cause mortality, myocardial infarction (MI) and/or urgent revas-
cularization during hospitalization. RUSH scoring is based on quartiles of predicted risk
of cardiac complication (Class I: <2% vs. IV: >15%). The TIMI score was implemented as
published. Compliance with current medical treatment recommendations for ACS was
assessed using a 4-point scale based on the aggregate use of aspirin, beta-blockers,
heparin and glycoprotein IIb/IIIa inhibitors. Results: The mean age was 67±14 years,
38% female, 86% Caucasian. 9% died, 6% had a MI, 27% underwent revascularization
but in only 1% was it urgent. The primary endpoint rates for TIMI score 0/1, 2, 3, 4, 5 and
6/7 were 11%,14%,13%, 11%,14% and 12% respectively (P=NS). The primary endpoint
rates for RUSH class I, II, III and IV were 6%, 8%, 9% and 17% respectively (P<0.001).
After controlling for compliance with established guidelines, the gradient of increased by
46% for each unit increase in RUSH class (P<0.001). Adjusting for the RUSH Class, the
odds ratio decreased by 54% for each unit increase in compliance (P<0.001).Conclu-
sions: The use of established risk scores overestimate event rates in unselected popula-
tions. Compliance with the current American College of Cardiology/American Heart
Association guidelines significantly improves prognosis regardless of the risk score.
1060-101 Angiographically Apparent Thrombus After Fibrinolytic 
Administration Is Associated With Impaired Epicardial 
Flow and Myocardial Perfusion in ST Elevation 
Myocardial Infarction Patients With Open Arteries
Ajay J. Kirtane, Dimitrios Karmpaliotis, Aaron Weisbord, Anh Bui, Sabina A. Murphy, 
Daniela Budiu, Ioanna Kosmidou, Julian M. Aroesty, Robert P. Giugliano, Christopher P. 
Cannon, Elliot M. Antman, Eugene Braunwald, C. Michael Gibson, Beth Israel 
Deaconess Medical Center, Boston, MA, TIMI Study Group, Harvard Medical School, 
Boston, MA
Background: Residual thrombus following fibrinolytic administration in ST-elevation myo-
cardial infarction (STEMI) may reflect a larger overall thrombotic burden, which may in
turn predispose to microembolization and impaired myocardial perfusion.
Methods: We hypothesized that angiographically-evident residual thrombus after fibrin-
olytic therapy in STEMI patients is associated with worsened indices of epicardial & myo-
cardial perfusion, even in the presence of an open infarct-related epicardial artery.
Clinical & angiographic data were analyzed from 929 patients with open arteries (TIMI
Flow Grade 2/3 at 60 minutes after fibrinolytic therapy) who were enrolled in the TIMI 14,
20, 23, and 24 trials in STEMI.
Results: Residual thrombus was found in 37.8% of patients (351/929). Baseline charac-
teristics associated with residual thrombus were non-LAD infarct location (72.1% in arter-
ies with thrombus vs. 60.7% in arteries without thrombus, p<0.0001) and a history of
hypercholesterolemia (27.6% vs. 21.5%, p=0.03). Residual thrombus was associated
with higher Corrected TIMI Frame Counts (CTFC) in the infarct-related artery (43.5 ±
36.2 with thrombus vs. 36.1 ± 23.9 without thrombus, n=907, p=0.0002), impaired
microvascular perfusion by TIMI Myocardial Perfusion Grade (57.0% TMPG 2/3 with
thrombus vs. 70.0% TMPG 2/3 without thrombus, n=929, p<0.0001), and a trend toward
a lower percentage of complete (>70% of baseline) ST-segment resolution (35.6% com-
plete resolution with thrombus vs. 40.3% complete resolution without thrombus, n=722,
p<0001). In multivariate regression models that incorporated age, time to treatment, gen-
der, a history of hypercholesterolemia, LAD location, and TIMI Flow Grade, residual
thrombus remained independently associated with slower flow by CTFC (p=0.01),
impaired TMPG (OR for TMPG 2/3 0.66, p=0.004) and less complete ST-segment resolu-
tion (OR for complete resolution 0.71, p=0.038) in patients with an open infarct-related
artery.
Conclusion: Angiographically-apparent thrombus after fibrinolytic administration is inde-
pendently associated with slower epicardial flow and impaired myocardial perfusion,
despite a patent epicardial artery.
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Background: Accurate risk assessment can guide clinical decision making in the man-
agement of acute coronary syndromes (ACS). Several risk models have been derived
from and validated in clinical trials and other selected patient cohorts, but their applicabil-
ity in the general population remains unclear.
Methods: In the prospective, observational Canadian ACS Registry, 4627 patients with
ACS were enrolled from 51 centres. Baseline patient data were recorded on standard
case report forms. We evaluated the risk models derived from the Platelet glycoprotein
IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT)
and the Global Registry of Acute Cardiac Events (GRACE) predicting in-hospital death
among patients with non-ST elevation (NSTE) ACS. Model discrimination was measured
by the c statistic which represents the area under the receiver operating characteristic
(ROC) curve. Calibration was assessed by the Hosmer-Lemeshow goodness-of-fit test,
where a low probability value indicates lack of fit.
Results: In-hospital mortality rates were 2.4% overall and 1.5% among the NSTE ACS
patients (N=2925; 63.2%) in our validation cohort. Both the PURSUIT and GRACE risk
models showed similar and good prognostic discrimination (c statistics= 0.84 and 0.83,
respectively; P=0.69 for difference). The GRACE model showed good calibration (Hos-
mer-Lemeshow P=0.40). In contrast, calibration in the PURSUIT model was poor (Hos-
mer-Lemeshow P<0.001) with consistent over-estimation of risks. Performance of the
GRACE model was similar when ST-elevation ACS patients were included.
Conclusions: Both the PURSUIT and GRACE models demonstrated good discrimina-
tion for in-hospital mortality in the Canadian ACS Registry. However, the GRACE risk
model, derived from a less selected population, provided superior calibration in risk
assessment across the spectrum of ACS. Our findings underscore the importance of risk
model validation in the general population to establish its generalizability before integra-
tion into clinical practice.
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1061-85 Trends in the Use of Effective Cardiac Medications in 
Patients With Acute Myocardial Infarction: The GRACE 
Experience
Robert J. Goldberg, Frederick A. Spencer, Ph. Gabriel Steg, José López-Sendón, Brian 
M. Kennelly, Marcus D. Flather, Gilles Montalescot, Enrique P. Gurfinkel, Polina 
Kuznetsova, Joel M. Gore, The GRACE Investigators, University of Massachusetts 
Medical School, Worcester, MA
Background There are increasing data supporting the routine use of certain effective
medications in the treatment of patients with acute myocardial infarction (AMI). However,
few data are available describing recent, as well as temporal, trends in utilization rates of
these medications in patients with AMI. Moreover, few contemporary data are available
from a multinational multicenter perspective.
Methods To examine recent (2000-2002) patterns in the use of effective cardiac medica-
tions, we examined data from 15,972 patients hospitalized with AMI at 94 hospitals in 14
countries included in the Global Registry of Acute Coronary Events (GRACE). The four
medications examined include aspirin, beta blockers, ACE inhibitors, and lipid-lowering
agents.
Results Overall, 1.5% of patients did not receive any of these 4 medications during the
acute hospitalization, 6.2% received only 1 treatment modality, 21.7% received any 2
medications, 38.6% received any 3 medications, and 32.0% received all 4 cardiac medi-
cations. There was a marked increase over time in the proportion of patients receiving all
4 medications during their index hospitalization (23.5% in 2000, n=7196; 40.7% in 2002,
n=6919). The most marked increases in the prescribing of these effective cardiac medi-
cations over time were noted for lipid-lowering agents (17% relative increase) followed by
increases in ACE inhibitors (10%). Use of aspirin and beta blockers remained relatively
stable during the periods examined. Increases in the prescribing of all 4 medications over
time were observed in various demographic and clinically defined subgroups. In addition,
there were marked increases over time in the prescribing of multiple cardiac medications
to patients in the different GRACE strata of low, moderate, and high risk.
Conclusion The results of this large multinational observational study provide insights
into changing prescribing patterns in the hospital management of AMI. Despite encour-
aging increases in the use of combinations of effective cardiac therapies, considerable
opportunities for increased utilization remain.
